Home › Products › Oncology › Lanolimus 0.5mg Tablet
Lanolimus 0.5mg Tablet
Salt Composition: EVEROLIMUS
- Manufacturer: MYLAN PHARMACEUTICALS PVT LTD
- Pack Size: 10 TABLET(s) IN A STRIP
- Dosage Form: TABLET
- Strength: 0.5MG
- Prescription Required
- Storage: Store Lanolimus tablet in the original package at room temperature (20°C to 25°C). Keep it out of reach from children.
₹552.00₹739.00
Inclusive of all taxes
Product Introduction
Lanolimus 0.5mg Tablet contains Everolimus, an mTOR kinase inhibitor that reduces the growth rate of certain abnormal cells, including cancer cells and cells associated with organ rejection. The tablet is indicated for treatment of advanced cancers including breast cancer, renal cell carcinoma, and pancreatic neuroendocrine tumours. It is also used to treat subependymal giant cell astrocytoma in patients with tuberous sclerosis complex. In transplant recipients, it prevents organ rejection in patients who have undergone kidney or liver transplantation by modulating immune response.
Everolimus increases susceptibility to bacterial and viral infections. Patients should maintain good oral hygiene, avoid live vaccines, and minimise sun exposure, as the medication increases photosensitivity. Grapefruit juice should be avoided as it may alter drug metabolism and efficacy.
Uses
Advanced breast cancer Advanced renal cell carcinoma Advanced pancreatic neuroendocrine tumours Treatment of subependymal giant cell astrocytoma
How it works
Lanolimus 0.5mg Tablet blocks a protein called mTOR (mammalian target of rapamycin) that helps cancer cells grow and divide. By inhibiting mTOR, this medicine slows down tumour growth and helps reduce the size of tumours. In transplant patients, it suppresses the immune system, so the body doesn’t reject the new organ.
Side Effects
Side effects are unwanted symptoms caused by medicines. Even though all drugs cause side effects, not everyone gets them. Serious Difficulty breathing, or swallowing Swelling of face, lips, tongue, throat Severe itching, red rash, raised bumps Common Infection (chills, increased temperature) Coughing Wheezing Excessive thirst High urine output or severely decreased urine output Tiredness Bleeding Increased appetite with weight loss
Expert Tips
Maintain good oral hygiene, as mouth ulcers are common. Avoid close contact with people who have received live vaccines. Inform your doctor if you’ve had hepatitis B, liver disease, high cholesterol, or heart conditions. Do not plan pregnancy during this treatment. A negative pregnancy test may be required before starting therapy. Carry a medical alert or inform healthcare providers before any surgery or dental procedure—this medicine may delay wound healing.
References
- Novartis Pharmaceuticals UK Limited, Electronic medicines compendium (EMC), [ Revised on June 2022] [ Accessed on 18th March 2023], https://www.medicines.org.uk/emc/files/pil.6658.pdf
- Jan Hasskarl; Everolimus; Recent Results in Cancer Research; Published on 2018; Accessed on 18/03/2023; https://pubmed.ncbi.nlm.nih.gov/30069763/
- Novartis Pharmaceuticals Corporation, US Food and Drug Administration, [ Revised on July 2012] [ Accessed on 18th March 2023], https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/022334s016lbl.pdf
- Goodman & Gilmanâs, The Pharmacological Basis of Therapeutics, Targeted therapy: tyrosine kinase inhibitors, monoclonal antibodies, and cytokines, 12th edition, 2011, 1743.
- KD Tripathi, Essentials of Medical Pharmacology, Immunosuppressant drugs, 7th edition, 2013, 878 - 882.
Safety Advice
Pregnancy: unsafe Lanolimus 0.5mg tablet is not recommended for pregnant women as it may cause fetal harm. Consult your doctor if you are pregnant or planning for pregnancy during the treatment.
Lungs: Consult your doctor It is not known whether Lanolimus 0.5mg tablet can be used for patients with lung problems. Consult your doctor if you have any lung diseases before starting the treatment.
Breastfeeding: unsafe Lanolimus 0.5mg tablet passes into your breast milk and harms your baby. It is unsafe to consume this tablet.
Disclaimer
The information provided on this page is intended for general informational purposes only and should not be considered as medical advice. Always consult a qualified healthcare professional before starting, stopping, or changing any medication. Self-medication can be harmful. Med For Rare does not endorse self-diagnosis or self-treatment.